SarahWaheedMD
Hematology • Washington, DCMyeloproliferative Disorder Hematology-Oncology
Hematology-Oncology at Johns Hopkins Kimmel Cancer Center, Sibley Memorial Hospital
Dr. Waheed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5255 Loughboro Rd NW
Washington, DC 20016Phone+1 202-660-6125
Summary
- Dr. Sarah Waheed is a hematologist at John Hopkins Kimmel Cancer Center at Sibley Memorial in Washington, DC appointed as Director of Developmental Therapeutics. She received her medical degree from King Edward Medical University and has been in practice 21 years. She specializes in multiple myeloma, waldenstrom's macroglobulinemia, poems syndrome, monoclonal gammopathy of unknown significance, and amylodiosis. She has more than 50 publications and over 500 citings.
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2007
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2004
King Edward Medical UniversityClass of 1996
Certifications & Licensure
DC State Medical License 2022 - 2024
AR State Medical License 2007 - 2023
MD State Medical License 2016 - 2023- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 150 citationsClinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)Rachael Sexton, Sarah Waheed, Saad Z. Usmani, Xenofon Papanikolaou, Bijay Nair
Blood. 2014-01-02 - 43 citationsJumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R. Sawyer, Erming Tian, Christoph Heuck, Joshua Epstein, Donald J. Johann
Blood. 2014-04-17 - 268 citationsExtramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z. Usmani, Christoph Heuck, Alan Mitchell, Jackie Szymonifka, Bijay Nair
Haematologica. 2012-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
